BPRG Bioprogress

RNS Number:5679D
BioProgress PLC
10 September 2007


For Immediate Release                                          10 September 2007


                                BioProgress plc

                          Notification of Shareholding


London, UK, 10 September 2007: BioProgress plc ('BioProgress' or the 'Company')
(AIM: BPRG; NASDAQ: BPRG), the specialty pharma and healthcare company, was
notified on 10 September 2007 that Credit Agricole Cheuvreux International Ltd
now has an interest in 7,710,679 shares of BioProgress Plc representing 4.00% of
the issued share capital of the Company.

                                    - ENDS -


For further information:

  BioProgress Plc                                        + 44 (0) 20 7098 9881
  Richard Trevillion, CEO
  Steve Martin, CDO
  Hiral Patel, CFO

  Buchanan Communications                                + 44 (0) 20 7466 5000
  Rebecca Skye Dietrich
  Mark Court


About BioProgress

BioProgress plc is an innovative specialty pharmaceutical and healthcare
business based around its platform technologies in polymer and film systems and
listed on London's AIM in May 2003. The company has over 80 patents granted or
in application within 24 patent families and has product development agreements
and strategic alliances with several global companies. As a virtually integrated
business, BioProgress has acquired sales and marketing resources within Europe
and the US as a launch mechanism for its own pharmaceutical products. The
business continues to develop innovative delivery mechanisms using its XGELTM
polymer technology, replacing the need to use animal-derived gelatine in
pharmaceutical and healthcare products. For further information please go to
www.bioprogress.com

Forward-Looking Information.

The Ordinary Shares of BioProgress plc are registered under the US Securities
and Exchange Act of 1934.  To the extent that this announcement contains certain
"forward-looking statements" within the meaning of the Private Securities
Litigation Reform Act of 1995, this paragraph applies.  These statements are
based on management's current expectations and are subject to uncertainty and
changes in circumstances.  Actual results may vary materially from the
expectations contained in the forward-looking statements.  The forward-looking
statements in this release include statements addressing future financial and
operating results and the timing and benefits of the reorganisation.  Detailed
information about factors pertinent to the business of the company that could
cause actual results to differ is set forth in the Company"s filings with the
Securities and Exchange Commission.  The Company is under no obligation to (and
expressly disclaim any such obligation to) update or alter its forward-looking
statements whether as a result of new information, future events or otherwise.
This announcement is for information only and does not constitute an offer or
invitation to acquire or dispose of any securities or investment advice.  The
distribution of the announcement and/or issue of securities in certain
jurisdictions may be restricted by law.  Persons into whose possession this
announcement comes are required to inform themselves about and to observe such
restrictions.


                      This information is provided by RNS
            The company news service from the London Stock Exchange
END
HOLSFMFFSSWSESU

Bioprogress (LSE:BPRG)
Historical Stock Chart
From Apr 2024 to May 2024

Bioprogress (LSE:BPRG)
Historical Stock Chart
From May 2023 to May 2024